Literature DB >> 27088377

The devil is in the T cells: relapsing after haploidentical hematopoietic cell transplantation.

M Byrne1, B N Savani1.   

Abstract

Mesh：

Substances：

Year:  2016        PMID： 27088377     DOI： 10.1038/bmt.2016.106

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  46 in total

1.  Chimeric antigen receptor T cells for sustained remissions in leukemia.

Authors:  Shannon L Maude; Noelle Frey; Pamela A Shaw; Richard Aplenc; David M Barrett; Nancy J Bunin; Anne Chew; Vanessa E Gonzalez; Zhaohui Zheng; Simon F Lacey; Yolanda D Mahnke; Jan J Melenhorst; Susan R Rheingold; Angela Shen; David T Teachey; Bruce L Levine; Carl H June; David L Porter; Stephan A Grupp
Journal:  N Engl J Med       Date:  2014-10-16       Impact factor: 91.245

2.  Drug-induced tolerance to allografts in mice. VII. Optimal protocol and mechanism of cyclophosphamide-induced tolerance in an H-2 haplotype-identical strain combination.

Authors:  H Mayumi; K Himeno; N Tokuda; K Nomoto
Journal:  Transplant Proc       Date:  1986-04       Impact factor: 1.066

3.  Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study.

Authors:  Yu Wang; Qi-Fa Liu; Lan-Ping Xu; Kai-Yan Liu; Xiao-Hui Zhang; Xiao Ma; Zhi-Ping Fan; De-Pei Wu; Xiao-Jun Huang
Journal:  Blood       Date:  2015-05-04       Impact factor: 22.113

4.  Comparison of Outcomes of Hematopoietic Cell Transplants from T-Replete Haploidentical Donors Using Post-Transplantation Cyclophosphamide with 10 of 10 HLA-A, -B, -C, -DRB1, and -DQB1 Allele-Matched Unrelated Donors and HLA-Identical Sibling Donors: A Multivariable Analysis Including Disease Risk Index.

Authors:  Asad Bashey; Xu Zhang; Katelin Jackson; Stacey Brown; Michelle Ridgeway; Melhem Solh; Lawrence E Morris; H Kent Holland; Scott R Solomon
Journal:  Biol Blood Marrow Transplant       Date:  2015-09-07       Impact factor: 5.742

5.  Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia.

Authors:  Max S Topp; Nicola Gökbuget; Gerhard Zugmaier; Petra Klappers; Matthias Stelljes; Svenja Neumann; Andreas Viardot; Reinhard Marks; Helmut Diedrich; Christoph Faul; Albrecht Reichle; Heinz-August Horst; Monika Brüggemann; Dorothea Wessiepe; Chris Holland; Shilpa Alekar; Noemi Mergen; Hermann Einsele; Dieter Hoelzer; Ralf C Bargou
Journal:  J Clin Oncol       Date:  2014-11-10       Impact factor: 44.544

6.  Follicular lymphomas can be induced to present alloantigen efficiently: a conceptual model to improve their tumor immunogenicity.

Authors:  J L Schultze; A A Cardoso; G J Freeman; M J Seamon; J Daley; G S Pinkus; J G Gribben; L M Nadler
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-29       Impact factor: 11.205

7.  Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma.

Authors:  Lauri M Burroughs; Paul V O'Donnell; Brenda M Sandmaier; Barry E Storer; Leo Luznik; Heather J Symons; Richard J Jones; Richard F Ambinder; Michael B Maris; Karl G Blume; Dietger W Niederwieser; Benedetto Bruno; Richard T Maziarz; Michael A Pulsipher; Finn B Petersen; Rainer Storb; Ephraim J Fuchs; David G Maloney
Journal:  Biol Blood Marrow Transplant       Date:  2008-11       Impact factor: 5.742

8.  Improved Outcome of Alternative Donor Transplantations in Patients with Myelofibrosis: From Unrelated to Haploidentical Family Donors.

Authors:  Stefania Bregante; Alida Dominietto; Anna Ghiso; Anna Maria Raiola; Francesca Gualandi; Riccardo Varaldo; Carmen Di Grazia; Teresa Lamparelli; Silvia Luchetti; Simona Geroldi; Lucia Casarino; Sarah Pozzi; Elisabetta Tedone; Maria Teresa Van Lint; Federica Galaverna; Giovanni Barosi; Andrea Bacigalupo
Journal:  Biol Blood Marrow Transplant       Date:  2015-10-09       Impact factor: 5.742

9.  T-replete haploidentical allogeneic transplantation using post-transplantation cyclophosphamide in advanced AML and myelodysplastic syndromes.

Authors:  R Devillier; S Bramanti; S Fürst; B Sarina; J El-Cheikh; R Crocchiolo; A Granata; C Chabannon; L Morabito; S Harbi; C Faucher; A Santoro; P-J Weiller; N Vey; C Carlo-Stella; L Castagna; D Blaise
Journal:  Bone Marrow Transplant       Date:  2015-11-09       Impact factor: 5.483

10.  IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.

Authors:  Peter Paschka; Richard F Schlenk; Verena I Gaidzik; Marianne Habdank; Jan Krönke; Lars Bullinger; Daniela Späth; Sabine Kayser; Manuela Zucknick; Katharina Götze; Heinz-A Horst; Ulrich Germing; Hartmut Döhner; Konstanze Döhner
Journal:  J Clin Oncol       Date:  2010-06-21       Impact factor: 50.717
View more
  1 in total

1.  Allodepleted T-cell immunotherapy after haploidentical haematopoietic stem cell transplantation without severe acute graft-versus-host disease (GVHD) in the absence of GVHD prophylaxis.

Authors:  Denis Claude Roy; Sylvie Lachance; Sandra Cohen; Jean-Sébastien Delisle; Thomas Kiss; Guy Sauvageau; Lambert Busque; Imran Ahmad; Lea Bernard; Nadia Bambace; Radia S Boumédine; Marie-Claude Guertin; Katayoun Rezvani; Stephan Mielke; Claude Perreault; Jean Roy
Journal:  Br J Haematol       Date:  2019-05-28       Impact factor: 6.998
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.